Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Support healthy cell function and healthy aging
After an initial 36-week period where all participants received Tirzepatide and lost on average about 21% of their body weight, 670 participants were randomized to either continue Tirzepatide or switch to placebo for an additional 52 weeks
BuddenKFGellatlySLWoodDLCooperMAMorrisonMHugenholtzPet alEmerging pathogenic links between microbiota and the gut-lung axis
L.et al (1984)
Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide Eli Lilly and Company announced results today from the SURPASS-CVOT trial, a head-to-head cardiovascular outcomes trial comparing two tirzepatide (Mounjaro) with dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease
.png)